share_log

信達生物:自願公告 - 國家藥品監督管理局受理IBI-351(KRAS G12C抑制劑)的新藥上市申請並納入優先審評

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED AND GRANTED PRIORITY REVIEW DESIGNATION TO THE NEW DRUG APPLICATION FOR IBI-351 (KRAS G12C INHIBITOR)

香港交易所 ·  Nov 23, 2023 19:15
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more